Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-prt4h Total loading time: 0.77 Render date: 2021-10-24T01:02:02.964Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Chapter 8 - Atypical antipsychotics and movement disorders

Published online by Cambridge University Press:  05 July 2015

Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999; 35: 5168.CrossRefGoogle ScholarPubMed
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000; 321: 1371–6.CrossRefGoogle ScholarPubMed
Glazer, WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000; 61 (Suppl 3): 1621.Google ScholarPubMed
Hippius, H. The history of clozapine. Psychopharmacology. 1989; 99: S3-S5.CrossRefGoogle ScholarPubMed
Meltzer, H. Introduction. Psychopharmacology. 1989; 99: S1-S2.CrossRefGoogle Scholar
Meltzer, HY. What’s atypical about atypical antipsychotic drugs? Curr Opin Pharmacol. 2004; 4: 53–7.CrossRefGoogle ScholarPubMed
Meltzer, HY, Matsubara, S, Lee, J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989; 251: 238–46.Google ScholarPubMed
Burris, KD, Molski, TF, Xu, C, Ryan, E, Tottori, K, Kikuchi, T, Yocca, FD, Molinoff, PB. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002; 302: 381–9.CrossRefGoogle ScholarPubMed
Kapur, S, Remington, G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001; 50: 873–83.CrossRefGoogle ScholarPubMed
Westerink, BHC. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol. 2002; 455: 118.CrossRefGoogle Scholar
Kapur, S, Zipursky, RB, Remington, G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999; 156: 286–93.Google Scholar
Caroff, SN, Mann, SC, Campbell, EC, Sullivan, KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002; 63 (Suppl 4): 12–9.Google ScholarPubMed
Hutton, P, Morrison, AP, Yung, AR, Taylor, PJ, French, P, Dunn, G. Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. Acta Psychiatr Scand. 2012; 126: 111.CrossRefGoogle Scholar
Woods, SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003; 64: 663–7.CrossRefGoogle Scholar
Rijcken, CA, Monster, TB, Brouwers, JR, de Jong-van den Berg, LT. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol. 2003; 23: 657–9.CrossRefGoogle ScholarPubMed
Lehman, AF, Lieberman, JA, Dixon, LB, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161 (2 Suppl): 156.Google Scholar
Jeste, DV, Okamoto, A, Napolitano, J, Kane, JM, Martinez, RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000; 157: 1150–5.CrossRefGoogle ScholarPubMed
Dolder, CR, Jeste, DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry. 2003; 53: 1142–5.CrossRefGoogle ScholarPubMed
Grant, MJ, Baldessarini, RJ. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother. 2005; 39: 1953.CrossRefGoogle ScholarPubMed
Kinon, BJ, Jeste, DV, Kollack-Walker, S, Stauffer, V, Liu-Seifert, H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28: 985–96.CrossRefGoogle Scholar
Miller, DD, Caroff, SN, Davis, SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Brit J Psychiat. 2008; 193: 279–88.CrossRefGoogle Scholar
Kane, JM, McGlashan, TH. Treatment of schizophrenia. Lancet. 1995; 346: 820–5.CrossRefGoogle ScholarPubMed
Hugenholtz, GW, Heerdink, ER, Stolker, JJ, Meijer, WE, Egberts, AC, Nolen, WA. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry. 2006; 67: 897903.CrossRefGoogle Scholar
Simpson, GM, Lindenmayer, JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997; 17: 194201.CrossRefGoogle ScholarPubMed
Castelao, JF, Ferreira, L, Gelders, YG, et al. The efficacy of the D2 and 5-HT2 antagonist risperidone (R64,766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res. 1989; 2: 411–5.CrossRefGoogle Scholar
Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995; 166:712–33.CrossRefGoogle Scholar
Lemmens, P, Brecher, M, Van Baelen, B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extra pyramidal symptoms. Acta Psychiatr Scand. 1999; 99: 160–70.CrossRefGoogle Scholar
Kopala, LC, Good, KP, Honer, WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Psychopharmacol. 1997; 17: 308–13.Google ScholarPubMed
Rosebush, PI, Mazurek, MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 1999; 52: 782–5.CrossRefGoogle Scholar
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373: 3141.CrossRefGoogle Scholar
Tarsy, D, Lungu, C, Baldessarini, RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011; 100: 601–16.CrossRefGoogle ScholarPubMed
Correll, CU, Schenk, EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008; 21: 151–6.CrossRefGoogle Scholar
Correll, CU, Leucht, S, Kane, JM, Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004; 161: 414–25.CrossRefGoogle ScholarPubMed
Ye, M, Tang, W, Liu, L, et al. Prevalence of tardive dyskinesia in chronic male inpatients with schizophrenia on long-term clozapine versus typical antipsychotics. Int Clin Psychopharmacol. 2014 May 16 [Epub ahead of print].
Bhidayasiri, R, Fahn, S, Weiner, WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81: 463–9.CrossRefGoogle Scholar
Trollor, JN, Chen, X, Sachdev, PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009; 23: 477–92.CrossRefGoogle Scholar
Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993; 77: 185202.CrossRefGoogle ScholarPubMed
Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45: 789–96.CrossRefGoogle Scholar
Essali, A, Al-Haj Haasan, N, Li, C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia (Review). Cochrane Database Syst Rev. 2009; 1: CD000059.Google Scholar
Asenjo Lobos, C, Komossa, K, Rummel-Kluge, C, Hunger, H, Schmid, F, Schwarz, S, Leucht, S. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010; 11: CD006633.Google Scholar
Diederich, NJ, Fénelon, G, Stebbins, G, Goetz, CG. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009; 5: 331–42.CrossRefGoogle ScholarPubMed
The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Eng J Med. 1999; 340: 757–63.PubMed
Factor, SA, Friedman, JH, Lannon, MC, Oakes, D, Bourgeois, K, and The Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: Results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001; 16: 135–9.3.0.CO;2-Q>CrossRefGoogle Scholar
Pollak, P, Tison, F, Rascol, O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004; 75: 689–95.CrossRefGoogle ScholarPubMed
Alvir, JMJ, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med. 1993; 329: 162–7.CrossRefGoogle ScholarPubMed
Barak, Y, Wittenberg, N, Naor, S, Kutzuk, D, Weizman, A. Clozapine in elderly psychiatric patients: tolerability, safety, end efficacy. Compr Psychiatry. 1999; 40: 320–5.CrossRefGoogle Scholar
Snowdon, J, Halliday, G. A study of the use of clozapine in old age psychiatry. Int Clin Psychopharmacol. 2011; 26: 232–5.CrossRefGoogle Scholar
Suttajit, S, Srisurapanont, M, Xia, J, Suttajit, S, Maneeton, B, Maneeton, N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2013; 5: CD007815.Google Scholar
Asmal, L, Flegar, SJ, Wang, J, Rummel-Kluge, C, Komossa, K, Leucht, S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013; 11: CD006625.Google Scholar
Evatt, ML, Jewart, D, Juncos, JL. ‘Seroquel’ treatment of psychosis in parkinsonism. Mov Disord. 1996; 11: 595.Google Scholar
Friedman, JH, Factor, SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord. 2000; 15: 201–11.3.0.CO;2-D>CrossRefGoogle ScholarPubMed
Henderson, MJ, Mellers, JDC. Psychosis in Parkinson’s disease: `between a rock and a hard place’. Int Rev Psychiatry. 2000; 12: 319–34.CrossRefGoogle Scholar
Seppi, K, Weintraub, D, Coelho, M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011; 26 (Suppl 3): S4280.CrossRefGoogle ScholarPubMed
Ondo, WG, Tintner, R, Voung, KD, Lai, D, Double-blind, Ringholz G., placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005; 20: 958–63.CrossRefGoogle Scholar
Rabey, JM, Prokhorov, T, Miniovitz, A, Dobronevsky, E, Klein, C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007; 22: 313–8.CrossRefGoogle Scholar
Shotbolt, P, Samuel, M, David, A. Quetiapine in the treatment of psychosis in Parkinson’s disease. Ther Adv Neurol Disord. 2010; 3: 339–50.CrossRefGoogle ScholarPubMed
Fernandez, HH, Friedman, JH, Jacques, C, Rosenfeld, M. Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord. 1999; 14: 484–7.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
Morgante, L, Epifanio, A, Spina, E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004; 27: 153–6.CrossRefGoogle ScholarPubMed
Merims, D, Balas, M, Peretz, C, Shabtai, H, Rater-blinded, Giladi N., prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006; 29: 331–7.Google ScholarPubMed
Simpson, GM, Lindenmayer, JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997; 17: 194201.CrossRefGoogle Scholar
Castelão, JF, Ferreira, L, Gelders, YG, Heylen, SL. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res. 1989; 2: 411–5.CrossRefGoogle ScholarPubMed
Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151: 825–35.Google ScholarPubMed
Claus, A, Bollen, J, De Cuyper, H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992; 85: 295305.CrossRefGoogle ScholarPubMed
Min, SK, Rhee, CS, Kim, CE, Kang, DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J. 1993; 34: 179–90.CrossRefGoogle ScholarPubMed
Hunter, RH, Joy, CB, Kennedy, E, Gilbody, SM, Song, F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003; 2: CD000440.Google Scholar
Gilbody, SM, Bagnall, AM, Duggan, L, Tuunainen, A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000; 3: CD002306.Google Scholar
Ford, B, Lynch, T, Greene, P. Risperidone in Parkinson’s disease. Lancet. 1994; 344: 681.CrossRefGoogle ScholarPubMed
Rich, SS, Friedman, JH, Ott, BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995; 56: 556–9.Google ScholarPubMed
Goetz, CG, Blasucci, LM, Leurgans, S, Pappert, EJ. Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients. Neurology. 2000; 55: 789–94.CrossRefGoogle ScholarPubMed
Duggan, L, Fenton, M, Rathbone, J, Dardennes, R, El-Dosoky, A, Indran, S. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005; 2: CD001359.Google Scholar
Komossa, K, Rummel-Kluge, C, Hunger, H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010; 3: CD006654.Google Scholar
Breier, A, Sutton, VK, Feldman, PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002; 52: 438–45.CrossRefGoogle Scholar
Ondo, WG, Levy, JK, Vuong, KD, Hunter, C, Jankovic, J. Olanzapine treatment for dopaminergic induced hallucinations. Mov. Disord. 2002; 17: 1031–5.CrossRefGoogle ScholarPubMed
Bagnall, A, Lewis, RA, Leitner, ML, Kleijnen, J. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2000; 2: CD001945.Google Scholar
Komossa, K, Rummel-Kluge, C, Hunger, H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009; 4: CD006627.Google Scholar
Schindehütte, J, Trenkwalder, C. Treatment of drug-induced psychosis in Parkinson’s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007; 109: 188–91.CrossRefGoogle ScholarPubMed
Pintor, L, Valldeoriola, F, Baillés, E, Martí, MJ, Muñiz, A, Tolosa, E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012; 35: 6166.CrossRefGoogle Scholar
Bhattacharjee, J, El-Sayeh, HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2008; 3: CD006617.Google Scholar
Khanna, P, Suo, T, Komossa, K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014; 1: CD006569.Google Scholar
Friedman, JH, Berman, RM, Goetz, CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord. 2006; 21: 2078–81.CrossRefGoogle Scholar
Barbato, L, Monge, A, Stocchi, F, Nordera, G. Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Funct Neurol. 1996; 11: 201–7.Google ScholarPubMed
Friedman, JH. Melperone is ineffective in treating Parkinson’s disease psychosis. Mov Disord. 2012; 27: 803–4.CrossRefGoogle Scholar
Wang, SM, Han, C, Lee, SJ, Patkar, AA, Masand, PS, Pae, CU. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013; 36: 223–38.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×